ALLERGOLOGIE

ALLERGOLOGIE Journal

publication venue for

Efficacy and safety of twice-yearly depemokimab in patients with chronic rhinosinusitis with nasal polyps (crswnp): the phase iii randomized, double-blind, placebo-controlled replicate ANCHOR-1/2 Trials 2025
Efficacy of tezepelumab on upper and lower airway outcomes in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in patients with and without comorbid asthma: results from the phase 3 waypoint study 2025
Pharmacokinetics and pharmacodynamics of twice-yearly depemokimab in the randomized, double-blind, placebo-controlled parallel phase III ANCHOR-1/2 Trials 2025
Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT) 2024
Treatment with dupilumab resulted in lower use of corticosteroids and antibiotics in patients with chronic rhinosinusitis with nasal polyps treated in real-world conditions in the United States 12 months 2024
Onset of Action, Maintenance and Persistence of Response to Dupilumab in chronic Rhinosinusitis with Nasal Polyps 2022
Onset of action, maintenance and persistence of response to dupilumab in chronic rhinosinusitis with nasal polyps 2022

International Standard Serial Number (ISSN)

0344-5062